Report date: July 30, 2026, before the market opens
Conference call: 8:30 a.m. ET (investor.regeneron.com)
Regeneron enters Q2 earnings with a familiar tension: Dupixent and Libtayo are growing rapidly, but the higher-value U.S. retinal franchise remains under pressure, while a recent Phase 3 failure has increased scrutiny of the pipeline.
The most important question is not whether Regeneron can beat a headline EPS estimate. It is whether management can show that:
REGN trades around $696, down approximately 10% from year-end 2025 but only modestly below its pre-fianlimab-failure level. That suggests much of the clinical setback has already been absorbed, leaving the quarterly reaction especially sensitive to EYLEA trends and management's forward commentary.
Public estimate aggregators generally place Q2 revenue around $3.8–$3.9 billion and adjusted EPS around $10.2–$10.7. However, estimate definitions vary considerably: one Zacks-derived data set shows an $8.00 current-quarter estimate, while other services show estimates above $10. (tipranks.com)
The principal complication is a previously disclosed $127 million acquired in-process R&D charge, expected to reduce both GAAP and non-GAAP diluted EPS by approximately $1.00. Investors should therefore compare reported EPS against estimates using the same treatment of that charge; otherwise, an apparent beat or miss may be largely definitional. (sec.gov)
For comparison, Q2 2025 results included:
| Metric | Q2 2025 |
|---|---|
| Revenue | $3.68B |
| Non-GAAP EPS | $12.89 |
| U.S. EYLEA HD sales | $393M |
| U.S. legacy EYLEA sales | $754M |
| Total U.S. EYLEA franchise | $1.15B |
| Global Dupixent sales | $4.34B |
| Global Libtayo sales | $377M |
The year-over-year EPS comparison is unusually difficult because Q2 2025 benefited from investment gains, a low tax rate and a much smaller IPR&D charge. The underlying product and collaboration trends should matter more than the raw EPS growth rate. (newsroom.regeneron.com)
The U.S. ophthalmology franchise remains the most important near-term issue for REGN.
In Q1:
Management provided unusually specific Q2 operating commentary:
Taken mechanically, those comments point toward EYLEA HD demand equivalent to roughly $515 million at Q1 pricing and legacy EYLEA in roughly the $390–$400 million area before allowing for price, channel inventory and mix. That would put the combined franchise near $900 million—well below Q2 2025's $1.15 billion.
A constructive print would show:
A weak result would be one where HD growth merely cannibalizes legacy EYLEA without slowing the decline in total retinal revenue. Additional aflibercept biosimilar launches expected in the second half make stabilization more urgent.
The EYLEA HD prefilled syringe is strategically important because retina specialists generally favor the convenience and workflow advantages of prefilled products. Regeneron had expected a decision on one or both pending manufacturing applications by the end of Q2. As of July 29, the company has not publicly announced an approval. Management should therefore be pressed for:
At a June 8 investor conference, Regeneron said there was no change to its expectation for action by the end of Q2. Missing that timeline without a clear explanation would be a negative qualitative development. (newsroom.regeneron.com)
Dupixent is the strongest part of the story. Q1 global sales reached $4.88 billion, up 33%, driven by broad demand across established indications and newer launches including COPD, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis. (investor.regeneron.com)
For Q2, investors should focus on:
A result around or above $5.3 billion would represent growth of roughly 22% from the prior year and keep Dupixent on a strong trajectory above a $20 billion annualized run rate.
Regeneron recorded $1.45 billion of Sanofi collaboration profit share in Q1. Management said the historical Sanofi development balance should be fully repaid by the end of Q2, allowing Regeneron to begin recording its full profit share in Q3. (investor.regeneron.com)
The earnings call should provide a clearer bridge for:
This accounting transition may be more important for forward estimates than the Q2 Dupixent sales number itself.
Libtayo was another Q1 highlight, with global sales of $438 million, up 54%. Growth came from advanced cutaneous squamous cell carcinoma, non-small-cell lung cancer and the newer adjuvant CSCC indication. However, management noted that the year-over-year comparison benefited partly from inventory timing. (investor.regeneron.com)
The key Q2 test is whether Libtayo can maintain a quarterly run rate above $400 million without channel assistance. Investors should look for:
Libtayo is increasingly important because it is wholly commercialized by Regeneron and could provide meaningful operating leverage if its growth persists.
Regeneron began 2026 with heavy pipeline investment. Q1 non-GAAP R&D expense was approximately $1.41 billion, up 19%, while non-GAAP SG&A was $560 million, up 4%. The company maintained full-year non-GAAP guidance of:
GAAP gross-margin guidance was reduced to 77%–78% following a temporary interruption at the Limerick manufacturing facility. Regeneron expected full production to resume by the end of Q2 and said product availability was not affected. (investor.regeneron.com)
A guidance raise is not essential, but a reduction—particularly one tied to retinal sales rather than increased pipeline investment—would be poorly received.
The biggest development since the Q1 report was the Phase 3 failure of fianlimab plus Libtayo in first-line metastatic melanoma.
The high-dose combination produced median progression-free survival of 11.5 months, versus 6.4 months for pembrolizumab, but missed statistical significance:
The low-dose arm also failed. No new safety signal was identified. Regeneron is continuing a Phase 3 head-to-head study against Opdualag, while the adjuvant melanoma study remains underway. (investor.regeneron.com)
The results were numerically encouraging but insufficient for the primary endpoint. Management now needs to explain:
The issue is broader than one asset. Investors are questioning whether Regeneron's high R&D spending is generating sufficiently predictable late-stage returns.
Near-term pipeline focus should move toward:
The Q2 call is an opportunity to replace the lost fianlimab narrative with a more prioritized and credible catalyst roadmap.
This is an EYLEA and credibility quarter, not primarily an EPS quarter.
Dupixent should remain the financial engine, and Libtayo is becoming a meaningful secondary contributor. But for REGN to re-rate, investors need evidence that EYLEA HD can do more than absorb patients from legacy EYLEA—they need it to stabilize the total retinal franchise.
The three most market-sensitive disclosures are likely to be:
A routine revenue and EPS beat accompanied by weak retinal trends or another vague manufacturing update may not be enough. Conversely, better-than-feared EYLEA stabilization, paired with sustained Dupixent growth and a clear catalyst roadmap, would make the current valuation look considerably more attractive.